Nachrichten zur FibroGen Aktie

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

…

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the…

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

…

FibroGen to Report First Quarter 2024 Financial Results

SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial…

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis…

FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

…

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

…

FibroGen, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

FibroGen to Report Third Quarter 2023 Financial Results

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023…

Dextromethorphan Market revenue to reach USD 550 Million by 2035, says Research Nester

Leading dextromethorphan market players include AstraZeneca plc, FibroGen, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Merck…

Insiderhandel: Aufsichtsrat verkauft Aktien von FibroGen im Wert von 3.820$

Henderson, Jeffrey William - Aufsichtsrat - Tag der Transaktion: 2023-08-04...…

FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended June 2023, but…

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 9.72% and 29.72%, respectively, for the quarter ended June 2023. Do the…

FibroGen Reports Second Quarter 2023 Financial Results

SAN FRANCISCO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the…

Form 8-K FIBROGEN INC For: Jul 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

FibroGen Taps Thane Wettig as Interim CEO on Conterno Exit

FibroGen Taps Thane Wettig as Interim CEO on Conterno Exit...…

FibroGen to Report Second Quarter 2023 Financial Results

SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023…

Insiderhandel: Aufsichtsrat verkauft Aktien von FibroGen im Wert von 5.380$

Henderson, Jeffrey William - Aufsichtsrat - Tag der Transaktion: 2023-07-11...…

Insiderhandel: Chief Executive Officer verkauft Aktien von FibroGen im Wert von 5.264$

Conterno, Enrique A. - Vorstand - Tag der Transaktion: 2023-07-07...…

Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?

Its pipeline is looking thin, and it might hit another speed bump quite soon....…

FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study

FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab…

FibroGen Shares Keep Dropping, Hit 52-Week Low

FibroGen Shares Keep Dropping, Hit 52-Week Low...…

Insiderhandel: Chief Commercial Officer verkauft Aktien von FibroGen im Wert von 13.075$

Wettig, Thane - Vorstand - Tag der Transaktion: 2023-06-23...…

FibroGen Shares Hit 52-Week Low After Pamrevlumab Trial Misses Primary Endpoint

FibroGen Shares Hit 52-Week Low After Pamrevlumab Trial Misses Primary Endpoint...…

FibroGen drives Scholar Rock, Omega lower after setback for lung disease candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : 1FG: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Form 8-K FIBROGEN INC For: Jun 26

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

FibroGen Shares Drop 74% After Pamrevlumab Trial Misses Primary Endpoint

FibroGen Shares Drop 74% After Pamrevlumab Trial Misses Primary Endpoint...…

XFRA : 1FG: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : INSTRUMENT_SUSPENSION - US31572Q8087

Instrument ID [8559] (1FG - US31572Q8087) suspended...…

FibroGen to discontinue late-stage trial of treatment for idiopathic pulmonary fibrosis, cut costs to extend cash runway to 2026

FibroGen Inc. FGEN said Monday it is discontinuing a late-stage trial of a treatment for idiopathic pulmonary fibrosis after it…

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company…

dpa-AFX ProFeed